scispace - formally typeset
R

Raquel Petrilli

Researcher at University of São Paulo

Publications -  39
Citations -  1312

Raquel Petrilli is an academic researcher from University of São Paulo. The author has contributed to research in topics: Drug delivery & Liposome. The author has an hindex of 14, co-authored 33 publications receiving 910 citations. Previous affiliations of Raquel Petrilli include University for International Integration of the Afro-Brazilian Lusophony & Sao Paulo State University.

Papers
More filters
Journal ArticleDOI

Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery.

TL;DR: The rapidly increasing knowledge of the many overexpressed biochemical makers in pathological sites has enabled the development of liposomes decorated with ligands for cell-surface receptors and active delivery, resulting in an optimal therapeutic effect devoid of side effects.
Journal ArticleDOI

Immunoliposomes: A review on functionalization strategies and targets for drug delivery.

TL;DR: This review addresses functionalization strategies for the non-covalent and covalent attachment of monoclonal antibodies and their fragments to liposomal surfaces and explores the main targeting possibilities with these ligands for the treatment of a variety of pathologies.
Journal ArticleDOI

Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy

TL;DR: The purpose of this study is to develop and characterize a co-loaded paclitaxel and rapamycin liposome and evaluate it for breast cancer efficacy both in vitro and in vivo, and it is expected that the formulation developed herein might be a contribution for future studies focusing on the clinical combination of paclitrixel andRapamycin.
Journal ArticleDOI

Delivery systems and local administration routes for therapeutic siRNA.

TL;DR: The main disease targets for the local delivery of siRNA to specific tissues or organs, including the skin, the lung, the eye, the nervous system, the digestive system and the vagina, were explored.
Journal ArticleDOI

Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.

TL;DR: The results support the clinical development of immunoliposomes for targeted delivery of PTX and RAP to HER2‐positive breast cancer and target the functionalization of liposomes with antibodies for overexpressed receptors on tumor surface to increase specificity and reduce side‐effects.